Compounds > di-n-propyldithiocarbamate
Page last updated: 2024-12-06

di-n-propyldithiocarbamate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Di-n-propyldithiocarbamate (DPDTC) is a sulfur-containing compound that has been studied for its potential use as a fungicide, bactericide, and anti-inflammatory agent. It is synthesized by reacting di-n-propylamine with carbon disulfide and an alkali metal hydroxide. DPDTC has been shown to have a broad spectrum of biological activity, including antifungal, antibacterial, and anti-inflammatory properties. It is thought to exert its effects by chelating metal ions, such as copper and zinc, which are essential for the growth and survival of microorganisms. DPDTC has also been shown to inhibit the production of inflammatory mediators, such as cytokines and prostaglandins. The mechanism of action of DPDTC is complex and not fully understood. It is a subject of ongoing research due to its potential applications in agriculture, medicine, and environmental protection.'

di-n-propyldithiocarbamate: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65312
CHEMBL ID2028021
SCHEMBL ID442021
MeSH IDM0161923

Synonyms (9)

Synonym
dipropyldithiocarbamic acid
4926-91-4
dpdtc
carbamodithioic acid, dipropyl-
25179-61-7
di-n-propyldithiocarbamate
SCHEMBL442021
CHEMBL2028021
DTXSID60179847
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (20.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (20.00)24.3611
2020's3 (60.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.66 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
ditiocarb
Ditiocarb: A chelating agent that has been used to mobilize toxic metals from the tissues of humans and experimental animals. It is the main metabolite of DISULFIRAM.. diethyldithiocarbamic acid : A member of the class of dithiocarbamic acids that is diethylcarbamic acid in which both of the oxygens are replaced by sulfur.		3.1950dithiocarbamic acidschelator;
copper chelator
pyrrolidine dithiocarbamate
pyrrolidine dithiocarbamic acid: spelled pyrolidine in J Nutr 1979 reference; RN given refers to parent cpd. pyrrolidine dithiocarbamate : A member of the class of dithiocarbamic acids that is the N-dithiocarboxy derivative of pyrrolidine.		1.9710dithiocarbamic acids;
pyrrolidines		anticonvulsant;
antineoplastic agent;
geroprotector;
neuroprotective agent;
NF-kappaB inhibitor;
radical scavenger
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Stomach
[description not available]		02.2510
Stomach Neoplasms
Tumors or cancer of the STOMACH.		02.2510
Breast Cancer
[description not available]		02.1710
Cancer of Ovary
[description not available]		02.1710
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.1710
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		02.1710
Acquired Immune Deficiency Syndrome
[description not available]		01.9710
Acquired Immunodeficiency Syndrome
An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.		01.9710